SLC22A25: A Potential Drug Target Or Biomarker for Diseases (G387601)

Target Name: SLC22A25

NCBI ID: G387601

SLC22A25

SLC22A25: A Potential Drug Target Or Biomarker for Diseases

SLC22A25 is a protein that belongs to the Solute carrier family 22 and is expressed in various tissues throughout the body. It is involved in the transport of various molecules, including small molecules, ions, and proteins across cell membranes. SLC22A25 is also known as isoform A and has been identified as a potential drug target or biomarker for various diseases.

SLC22A25 is a member of the SLC22 family, which includes several related proteins that share similar structures and functions. These proteins are involved in the transport of various molecules across cell membranes and play a crucial role in maintaining the integrity of cellular membranes. The SLC22 family proteins are characterized by the presence of a unique transmembrane domain, which is responsible for the protein's ability to interact with cell membranes and facilitate the transport of various molecules.

SLC22A25 is a 25kDa protein that is expressed in various tissues throughout the body. It is highly conserved, with a calculated amino acid sequence of 210 amino acids and a calculated protein mass of 22kDa. SLC22A25 is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the liver, heart, and kidneys. It is also expressed in other tissues, including the brain, pancreas, and red blood cells.

SLC22A25 is involved in the transport of various molecules across cell membranes, including small molecules, ions, and proteins. It has been shown to be involved in the transport of various substances, including drugs, toxins, and other molecules that are harmful to the body. For example, SLC22A25 has been shown to be involved in the transport of alcohol and other drugs across cell membranes.

SLC22A25 has also been identified as a potential drug target or biomarker for various diseases. For example, SLC22A25 has been shown to be involved in the transport of certain drugs, including chemotherapy drugs, across cell membranes. This suggests that targeting SLC22A25 may be a promising strategy for the development of new cancer therapies. Additionally, SLC22A25 has also been shown to be involved in the transport of toxins, such as the neurotoxin BMAA, across cell membranes. This suggests that targeting SLC22A25 may also be a promising strategy for the development of new neurodegenerative diseases.

SLC22A25 is also involved in the regulation of various cellular processes, including cell signaling, DNA replication, and cell growth. For example, SLC22A25 has been shown to be involved in the regulation of the DNA replication process, as well as the regulation of cell signaling pathways. This suggests that targeting SLC22A25 may be a promising strategy for the development of new therapeutics for various diseases.

In conclusion, SLC22A25 is a protein that is involved in the transport of various molecules across cell membranes and has been identified as a potential drug target or biomarker for various diseases. Further research is needed to fully understand the role of SLC22A25 in cellular processes and to develop new therapeutics for various diseases.

Protein Name: Solute Carrier Family 22 Member 25

The "SLC22A25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets